Diabetes mellitus is a common disease all over the world and the number of patients with this disease is growing every year. According to the Order of the Government of the Russian Federation No. 1495-r dated June 7, 2023, the Strategy for the Development of the Pharmaceutical Industry until 2030 includes the production of high-quality and competitive drugs in the external and domestic markets, as well as the production of Russian drugs in a full production cycle in the territory of the Russian Federation. To conduct a comparative analysis, a database was preliminarily compiled for three pharmaceutical markets: Russian, European and American. Data on the range of insulin drugs in the Russian market were obtained from the State Register of Medicines of the Ministry of Health of Russia, data on the range of insulin drugs on the European market were obtained from the European Medicines Agency (EMA), data on the range of insulin drugs on the American market were obtained from the Food and Drug Administration (FDA). The conducted analysis of the databases showed that in such issues as the number of medicinal products registered by Russian companies on the domestic market, the pharmaceutical industry complies with the goals of the Strategy, but the number of Russian-made medicinal products registered on other markets does not correspond to the level of competitiveness declared by the President of the Russian Federation.

Diabetes, production, import substitution, insulin.